Clobetasol Propionate is a drug owned by Eyenovia Inc. It is protected by 2 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 09, 2036. Details of Clobetasol Propionate's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11376262 | Method of treating an inflammatory or infectious disease |
May, 2036
(11 years from now) | Active |
| US10588913 | Aqueous suspension agent containing glucocorticosteroid nanoparticles |
May, 2036
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Clobetasol Propionate's patents.
Latest Legal Activities on Clobetasol Propionate's Patents
Given below is the list of recent legal activities going on the following patents of Clobetasol Propionate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Mar, 2023 | US10588913 |
| Patent Issue Date Used in PTA Calculation Critical | 05 Jul, 2022 | US11376262 |
| Recordation of Patent Grant Mailed Critical | 05 Jul, 2022 | US11376262 |
| Email Notification Critical | 16 Jun, 2022 | US11376262 |
| Issue Notification Mailed Critical | 15 Jun, 2022 | US11376262 |
| Application Is Considered Ready for Issue Critical | 25 May, 2022 | US11376262 |
| Dispatch to FDC | 25 May, 2022 | US11376262 |
| Issue Fee Payment Received Critical | 20 May, 2022 | US11376262 |
| Issue Fee Payment Verified Critical | 08 May, 2022 | US11376262 |
| Mail Response to 312 Amendment (PTO-271) Critical | 08 Apr, 2022 | US11376262 |
FDA has granted several exclusivities to Clobetasol Propionate. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Clobetasol Propionate, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Clobetasol Propionate.
Exclusivity Information
Clobetasol Propionate holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Clobetasol Propionate's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 04, 2027 |
US patents provide insights into the exclusivity only within the United States, but Clobetasol Propionate is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Clobetasol Propionate's family patents as well as insights into ongoing legal events on those patents.
Clobetasol Propionate's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Clobetasol Propionate's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 09, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Clobetasol Propionate Generic API suppliers:
Clobetasol Propionate is the generic name for the brand Clobetasol Propionate. 35 different companies have already filed for the generic of Clobetasol Propionate, with Taro having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Clobetasol Propionate's generic
Alternative Brands for Clobetasol Propionate
Clobetasol Propionate which is used for treating inflammation., has several other brand drugs using the same active ingredient (Clobetasol Propionate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Galderma Labs |
| ||
| Galderma Labs Lp |
| ||
| Norvium Bioscience |
| ||
| Primus Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Clobetasol Propionate, Clobetasol Propionate's active ingredient. Check the complete list of approved generic manufacturers for Clobetasol Propionate
About Clobetasol Propionate
Clobetasol Propionate is a drug owned by Eyenovia Inc. It is used for treating inflammation. Clobetasol Propionate uses Clobetasol Propionate as an active ingredient. Clobetasol Propionate was launched by Eyenovia in 2024.
Approval Date:
Clobetasol Propionate was approved by FDA for market use on 04 March, 2024.
Active Ingredient:
Clobetasol Propionate uses Clobetasol Propionate as the active ingredient. Check out other Drugs and Companies using Clobetasol Propionate ingredient
Treatment:
Clobetasol Propionate is used for treating inflammation.
Dosage:
Clobetasol Propionate is available in suspension/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.05% | SUSPENSION/DROPS | Prescription | OPHTHALMIC |